Catalyst’s scientists focused on creating improved, next-generation, pro-coagulant proteases and novel proteases that cleave targets in the complement cascade
Improving Protease Drugs
Catalyst created improved protease variants using a rational design strategy. In this process, a small number of amino acids in a given protease are substituted in an iterative fashion with different amino acids to improve a molecule’s biological properties. This approach led to product candidates that have the potential to be improved versions of Factor VIIa, Factor IX, and Factor Xa that may have many important and differentiated advantages including higher activity, longer duration of action, and improved safety.
Creation of Novel Protease Drugs
Catalyst has developed and optimized a propriety method to create novel proteases that currently make up part of our partnering portfolio, including our anti-C3 protease CB 2782 for dry age-related macular degeneration (AMD) and delayed graft function (DGF). In October 2017 Catalyst announced a strategic research collaboration with Mosaic Biosciences to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry AMD and other serious inflammatory retinal diseases. Mosaic will improve the pharmacokinetic (PK) properties of Catalyst’s lead anti-C3 proteases, with a goal of delivering product candidates that have a target profile of at least once quarterly intravitreal (IVT) dosing in humans and better potency compared with competitors with current monthly or bi-monthly dosing. Catalyst maintains global commercial rights and is exploring licensing opportunities for its anti-complement programs in Dry AMD and DGF.